Symmetra Bio
↗Doha, Qatar
Symmetra Bio is an early-stage biotechnology company developing first-in-class small molecule allosteric modulators of Sestrin2 (SESN2). The company's platform focuses on restoring cellular homeostasis and stress response mechanisms to treat chronic conditions such as heart failure, diabetic nephropathy, and metabolic syndrome.
The company is a spin-off based on the academic research of Dr. Hassaan Rathore, leveraging the role of Sestrin2 as a leucine sensor and regulator of the mTORC1 and AMPK pathways. Symmetra Bio aims to address the high unmet need in cardiovascular and renal diseases where traditional therapies fail to prevent progressive organ damage.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Cardiovascular & Metabolic Therapeutics
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue
Founded:2023
Ownership:private
Status:operating
FUNDING
Stage:Seed
Investors:Qatar Science & Technology Park (QSTP), Qatar University (Potential IP partner)
PIPELINE
Stage:Discovery
Lead Drug Stage:Preclinical
Modalities:Small molecule, Allosteric modulators
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Qatar University (Research collaboration), Qatar Science & Technology Park (Incubation)
COMPETITION
Position:Niche Player
Competitors:Navitor Pharmaceuticals, Aeovian Pharmaceuticals, Tornard Therapeutics
LEADERSHIP
Key Executives:
Hassaan Anwer Rathore - Founder & CSO
Scientific Founders:Dr. Hassaan Anwer Rathore
LINKS
Website:symmetrabio.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Symmetra Bio. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.